Tharimmune, Inc.
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell THAR and other ETFs, options, and stocks.About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure.
CEORandy D. Milby
CEORandy D. Milby
Employees2
Employees2
HeadquartersBridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded2017
Founded2017
Employees2
Employees2
THAR Key Statistics
Market cap3.57M
Market cap3.57M
Price-Earnings ratio-0.17
Price-Earnings ratio-0.17
Dividend yield—
Dividend yield—
Average volume78.89K
Average volume78.89K
High today$1.36
High today$1.36
Low today$1.26
Low today$1.26
Open price$1.27
Open price$1.27
Volume25.32K
Volume25.32K
52 Week high$6.39
52 Week high$6.39
52 Week low$0.952
52 Week low$0.952
People also own
Based on the portfolios of people who own THAR. This list is generated using Robinhood data, and it’s not a recommendation.